Kirkland & Ellis is representing Vista Equity Partners in the transaction, and Fenwick & West is representing Model N. Vista Equity Partners, which announced its definitive...
You must be a Standard 1 Year member to access this content.
Skadden advised Vertex Pharmaceuticals Incorporated, while Fenwick & West advised Alpine in the transaction. Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc. have entered into a definitive...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Achieve Life Sciences, while Sullivan & Worcester represented Lake Street Capital Markets, LLC and JonesTrading Institutional Services LLC on the transaction. Achieve...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Achieve Life Science, while Sullivan & Worcester represented Lake Street Capital Markets in the transaction. Achieve Life Sciences, Inc. (Nasdaq: ACHV), a...
You must be a Standard 1 Year member to access this content.
Fenwick & West LLP represented Chinook Therapeutics, Inc. on the transaction, while Hogan Lovells US LLP represented Novartis AG. Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company, announced...
You must be a Standard 1 Year member to access this content.
Skadden, Arps, Slate, Meagher & Flom advised Stryker on the deal, while Fenwick & West represented Vocera Communications. Debevoise & Plimpton advised Evercore LLC as financial...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised Amunix on the deal, while Weil, Gotshal & Manges advised Sanofi. Amunix, an immuno-oncology company, announced its pending acquisition by Sanofi, a global...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised DICE Therapeutics on the deal. DICE Therapeutics (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of...
You must be a Standard 1 Year member to access this content.
Fenwick & West LLP advised Impel NeuroPharma on the deal. Impel NeuroPharma, a late-stage pharmaceutical company developing transformative therapies for diseases of the central nervous system, announced its...
You must be a Standard 1 Year member to access this content.
